NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Life-saving Vaccines > Human trials of aerosol-based TB vaccine begin

Human trials of aerosol-based TB vaccine begin

13 July 2022 · Listed under Life-saving Vaccines

University of Oxford researchers have begun recruiting for a phase I clinical trial of a tuberculosis vaccine in human volunteers to develop a new way to test the efficacy of future TB vaccines.

Photo by CDC via Unsplash

The study is led by the Director of the NIHR Oxford Biomedical Research Centre (BRC), Helen McShane, who is a professor of vaccinology.

Until now, it has not been possible to use a human challenge study – where people are intentionally infected with a disease – to test a new tuberculosis vaccine because humans cannot be safely infected with the bacteria causing TB.

In this new study, however, volunteers will be ‘challenged’ with the BCG vaccine administered through aerosol inhalation, with the aim of mimicking how TB bacteria enter the lungs.

The BCG vaccine contains a similar bacterium to the one causing TB and has safely been used as an injectable vaccine for decades.

The research team will assess how much BCG is recoverable from lung-washing samples taken from volunteers after vaccination. If it can be demonstrated that this approach is well tolerated by the participants, then this method could be used to test new TB vaccines in the future.

The TB044 study, which is supported by the Oxford BRC, plans to recruit a sample of 12 people aged 18 to 50, who are in good health and have previously received a BCG vaccine. They will be split into four groups, each of which will get progressively stronger doses as long as there have been no side effects.

Following vaccination, participants will be monitored closely over six months and treated accordingly if they experience any adverse events. Results are expected in 2023.

Professor McShane said: “The TB044 study is the latest step in developing a safe human challenge model which mimics the way that tuberculosis infection occurs. By building on previous studies from my lab in the Jenner Institute, we hope to be able to use a safe BCG challenge model to understand more about what happens in the early stages of tuberculosis infection.

“This model could help us to both discover new markers of protection against tuberculosis, but also in the future as a way to test new vaccine regimes. Developing a successful vaccine against tuberculosis is an important piece in our armoury in combatting this important infectious disease which could save millions of lives.”

Timothy Fredsgaard-Jones, Clinical Research Fellow at the Jenner Institute and Lead Clinician of the trial, said: “Tuberculosis is the leading global cause of death from a single bacterium, infecting millions of people worldwide every year. Unfortunately, a significant proportion continue to get sick and die, even with antibiotics. Having an effective vaccine is really important in changing this.

“A safe BCG challenge model would allow us to test novel vaccine regimens more quickly and understand which ones have the best chance of working. This trial gives people the opportunity of taking part in research which could ultimately improve the health of people all around the world.”

As well as the Oxford BRC, the US-based National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) are funding the study.

Volunteers interested in enrolling on the study can do so online.

← Oxford BRC’s ability to deliver rapid COVID-19 research response highlighted
Malaria booster vaccine continues to meet WHO efficacy goal →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre